B+
Bull case
20%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
SRZN
SurrozenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+85.5
Score
AI commentary
Sentiment is cautiously constructive but low-signal. The latest primary update supports cash runway, a Boehringer milestone, and an H2 2026 IND target, while the packet lacks verified analyst revisions, options data, short-interest data, social coverage, or attributed post-earnings price reaction. The setup is better viewed as a monitored speculative biotech than a high-conviction long. [#SEC-8K-2026-05-06]
RankAlpha Sentiment Codex - 2026-08-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04catalystCash and partner-milestone supportMedium impact
Q1 disclosures showed $106.9 million of cash and a $5.0 million Boehringer Ingelheim collaboration milestone, supporting near-term runway but not proving clinical efficacy. [#SEC-8K-2026-05-06]
2026-10-31catalystPotential IND clearance and second PIPE closingHigh impact
The packet indicates that FDA clearance of the SZN-8141 IND by October 31, 2026 could trigger a second PIPE closing and additional development capital. This is a material runway opportunity but carries regulatory, timing, and dilution risk. [#10-K-2026-03-23]
2026-11-02eventSZN-8141 IND submissionHigh impact
Surrozen remains on track to submit an IND for SZN-8141 in the second half of 2026. Timely filing would improve clinical visibility; delay would weaken the thesis. [#SEC-8K-2026-05-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology